Effect of combined nasal spray of olopatadine hydrochloride and mometasone furoate on the control of allergic rhinitis and outcomes of concomitant asthma in children

Objective.  To evaluate the effect of combination nasal spray containing olopatadine hydrochloride and mometasone furoate (OLO/MF) on the control of AR and the outcomes of concomitant bronchial asthma in children of different ages.

Materials and Methods. Sixty children of two age groups were included in an open-label observational study with a duration of 56-84 days: 7-11 years old (n=24) and 12-17 years old (n=36) with uncontrolled seasonal and/or perennial AR and concomitant, partially or uncontrolled mild or moderate, asthma, who were treated with age-appropriate dosage of OLO/MF nasal spray.  Therapy of asthma under the terms of the study protocol remained unchanged. The severity of AR symptoms was assessed using a visual analogue scale. Control of concomitant asthma was determined by validated questionnaires:  сAST/AST, ACQ, and quality of life for children with asthma by PAQLQ(s) questionnaire. All study participants underwent the following instrumental and laboratory assessments twice: external respiratory function with bronchodilation test, measurement of nitric oxide in exhaled air (FeNO), nasal secretion sampling and rhinocytogram, venous blood sampling and clinical blood analysis, and determination of eosinophilic cationic protein level. At intermediate visits after 28(28-30) days, spirometry was performed. At each visit, patients were asked to fill out questionnaires.

Results. Treatment of AR with nasal spray of a fixed combination OLO/MF revealed statistically significant reduction of AR and asthma symptoms, as well as showed a correlation between the improvement of AR and asthma control and the quality of life of children with asthma. With the improvement of AR and asthma control, functional indices such as FEV1 improved, and the level of eosinophils in nasal secretion showed a statistically significant decrease.

Conclusion. The rapid and effective achievement of AR control in children with a combined OLO/MF nasal spray may allow for improved control of concomitant asthma and quality of life without escalation of baseline anti-asthmatic therapy.